183 related articles for article (PubMed ID: 1364172)
1. Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications.
Roncalli M; Doglioni C; Springall DR; Papotti M; Pagani A; Polak JM; Ibrahim NB; Coggi G; Viale G
Diagn Mol Pathol; 1992 Jun; 1(2):129-35. PubMed ID: 1364172
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
3. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors.
Lohmann DR; Fesseler B; Pütz B; Reich U; Böhm J; Präuer H; Wünsch PH; Höfler H
Cancer Res; 1993 Dec; 53(23):5797-801. PubMed ID: 8242638
[TBL] [Abstract][Full Text] [Related]
4. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
[TBL] [Abstract][Full Text] [Related]
5. Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors.
Naranjo Gómez JM; Bernal JF; Arranz PG; Fernández SL; Roman JJ
Arch Pathol Lab Med; 2014 Jul; 138(7):936-42. PubMed ID: 24978920
[TBL] [Abstract][Full Text] [Related]
6. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.
Wang DG; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1998 Mar; 184(3):247-51. PubMed ID: 9614375
[TBL] [Abstract][Full Text] [Related]
7. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis.
Sampietro G; Tomasic G; Collini P; Biganzoli E; Boracchi P; Bidoli P; Pilotti S
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):49-56. PubMed ID: 10937049
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
Brambilla E; Negoescu A; Gazzeri S; Lantuejoul S; Moro D; Brambilla C; Coll JL
Am J Pathol; 1996 Dec; 149(6):1941-52. PubMed ID: 8952529
[TBL] [Abstract][Full Text] [Related]
10. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.
Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G
Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207
[TBL] [Abstract][Full Text] [Related]
11. Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids.
Komminoth P; Roth J; Lackie PM; Bitter-Suermann D; Heitz PU
Am J Pathol; 1991 Aug; 139(2):297-304. PubMed ID: 1651057
[TBL] [Abstract][Full Text] [Related]
12. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.
Wu M; Wang B; Gil J; Sabo E; Miller L; Gan L; Burstein DE
Am J Clin Pathol; 2003 May; 119(5):696-702. PubMed ID: 12760288
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of neural-cadherin in pulmonary epithelial tumours.
Zynger DL; Dimov ND; Ho LC; Laskin WB; Yeldandi AV
Histopathology; 2008 Feb; 52(3):348-54. PubMed ID: 18269586
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.
Jiang SX; Kameya T; Sato Y; Yanase N; Yoshimura H; Kodama T
Am J Pathol; 1996 Mar; 148(3):837-46. PubMed ID: 8774138
[TBL] [Abstract][Full Text] [Related]
15. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms.
Barbareschi M; Girlando S; Mauri FA; Arrigoni G; Laurino L; Dalla Palma P; Doglioni C
J Pathol; 1992 Apr; 166(4):343-50. PubMed ID: 1355531
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis.
Wang DG; Johnston CF; Anderson N; Sloan JM; Buchanan KD
J Pathol; 1995 Apr; 175(4):397-401. PubMed ID: 7790993
[TBL] [Abstract][Full Text] [Related]
17. Genetic alteration in carcinoid tumors of the lung.
Sugio K; Osaki T; Oyama T; Takenoyama M; Hanagiri T; Morita M; Yamazaki K; Nagashima A; Nakahashi H; Maehara Y; Yasumoto K
Ann Thorac Cardiovasc Surg; 2003 Jun; 9(3):149-54. PubMed ID: 12875635
[TBL] [Abstract][Full Text] [Related]
18. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.
Folpe AL; Gown AM; Lamps LW; Garcia R; Dail DH; Zarbo RJ; Schmidt RA
Mod Pathol; 1999 Jan; 12(1):5-8. PubMed ID: 9950155
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of p53 mutations in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma.
Wang X; Rao MS; Yeldandi AV
Mod Pathol; 1995 Dec; 8(9):919-23. PubMed ID: 8751332
[TBL] [Abstract][Full Text] [Related]
20. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
